

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Life360, Inc.
ARBN	629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alexander (Alex) Haro
Date of last notice	7 June 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	8 June 2023 (PDT) (being 9 June 2023 AEST)
No. of securities held prior to change	<ul style="list-style-type: none">• 862,506 shares of common stock (Shares) (equivalent to 2,587,518 Chess Depositary Interests (CDIs))• 3,900,447 CDIs• 407,837 Options overs Shares (Options)• 91,905 CDIs held by ICCA Labs, LLC¹• 10,191 Restricted Stock Units (RSUs)
Class	(i) Shares & RSUs (ii) Shares & CDIs

¹ Alex Haro is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of CDIs attributable to Alex Haro by reason of his membership interest in ICCA Labs, LLC is 91,905

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	(i) 1,100 Shares (ii) 1,300,149 Shares
Number disposed	(i) 1,100 RSUs (having vested) (ii) 3,900,447 CDIs (having been transmuted to Shares)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(i) Shares are issued following the vesting and settlement of 1,100 RSUs which were granted in lieu of the payment of Board Fees ² . (ii) Nil. CDIs were converted to Shares – no change in net holdings and no consideration required for conversions
No. of securities held after change	<ul style="list-style-type: none"> • 2,163,755 Shares (equivalent to 6,491,265 CDIs) • 407,837 Options • 91,905 CDIs held by ICCA Labs, LLC • 9,091 RSUs
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(i) Issue of Shares following the vesting and settlement of RSUs. (ii) Conversion/transmutation of 3,900,447 CDIs to 1,130,149 Shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

² As per the Appendix 3Y lodged with the ASX on 27 May 2022, 4,397 RSUs were granted in lieu of the payment of US\$36,000 of Board Fees.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.